SAB Biotherapeutics is advancing a new class of immunotherapies with targeted, fully human polyclonal antibodies for the treatment of Covid-19, diabetes, organ transplant & flu.

Pharmaceutical

SAB Biotherapeutics

Eddie J. Sullivan

Trenton Klimper

Angela Parizek

Jacob Spade

Dr. Carlos Carrillo, MS, PhD.

Alexandra Kropotova

Christoph Bausch

The Research Team at SAB Biotherapeutics is responsible for developing and optimizing cutting-edge immunotherapy solutions using fully human polyclonal antibodies. They conduct experimental research, evaluate clinical data, and produce antigens essential for treating diseases such as Covid-19, diabetes, organ transplant complications, and the flu.

Research Team

Leadership Team

Corporate Management Team

Research Team

About

Team members

Other teams at SAB Biotherapeutics

Leadership Team

Corporate Management Team